Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects, Including Food Effect, Mass Balance, and Metabolite Profiling
Latest Information Update: 13 Aug 2020
At a glance
- Drugs ACT 1014 6470 (Primary)
- Indications Immunological disorders
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 11 Aug 2020 Status changed from active, no longer recruiting to completed.
- 08 Jan 2020 Planned End Date changed from 18 Aug 2020 to 28 Jul 2020.
- 08 Jan 2020 Planned primary completion date changed from 18 Aug 2020 to 28 Jul 2020.